About: Relative COVID-19 viral persistence and antibody kinetics

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Relative COVID-19 viral persistence and antibody kinetics Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Relative COVID-19 viral persistence and antibody kinetics
Creator	Huang, Chung-Guei Hsiao, Mei-Jen Shih, Shin-Ru Tsao, Kuo-Chien Hsieh, Yu-Chia Huang, Ching-Tai Yang, Cheng-Ta Dutta, Avijit Chang, Pi-Yueh
Source	MedRxiv
abstract	Importance: The COVID-19 antibody response is a critical indicator for evaluating immunity and also serves as the knowledge base for vaccine development. The picture is still not clear because of many limitations including testing tools, time of sampling, and the unclear impact of varying clinical status. In addition to these problems, antibody levels may not be equivalent to protective capacity. Objective: To define the key factor for the different patterns of COVID-19 antibody response. Design: We elucidated the antibody response with time-series throat and serum samples for viral loads and antibody levels, then used a neutralization test to evaluate protectiveness. Setting: A medical center that typically cares for patients with moderate to severe diseases. Because of the low prevalence of COVID-19 in Taiwan and local government policy, however, we also admit COVID-19 patients with mild disease or even those without symptoms for inpatient care. Participants: RT-PCR-confirmed COVID-19 patients. Results: We found that only patients with relative persistence of virus at pharynx displayed strong antibody responses that were proportional to the pharyngeal viral load. They also had proportional neutralization titers per unit of serum. Although antibody levels decreased around 2 weeks after symptom onset, the neutralization efficacy per unit antibody remained steady and even continued to increase over time. The antibody response in patients with rapid virus clearance was weak, but the neutralization efficacy per unit antibody in these patients was comparable to those with persistent presence of virus. The deceased were with higher viral load, higher level of antibody, and higher neutralization titers in the serum, but the neutralization capacity per unit antibody is relatively low. Conclusions and Relevance: Strong antibody response depends on the relative persistence of the virus, instead of the absolute virus amount. The antibody response is still weak if large amount of virus is cleared quickly. The neutralization efficacy per unit antibody is comparable between high and low antibody patterns. Strong antibody response contains more inefficient and maybe even harmful antibodies. Low antibody response is also equipped with a capable B cell pool of efficient antibodies, which may expand with next virus encounter and confer protection.
has issue date	2020-07-02(xsd:dateTime)
bibo:doi	10.1101/2020.07.01.20143917
has license	medrxiv
sha1sum (hex)	524645f40b95eed16d3aec4757dcf12fcbf5370f
schema:url	https://doi.org/10.1101/2020.07.01.20143917
resource representing a document's title	Relative COVID-19 viral persistence and antibody kinetics
resource representing a document's body	covid:524645f40b95eed16d3aec4757dcf12fcbf5370f#body_text
is schema:about of	named entity 'antibody' named entity 'viral' named entity 'Relative' named entity 'antibody response' named entity 'key factor' named entity 'COVID-19' named entity 'ADE' named entity 'virus' named entity 'titer' named entity 'antibody response' named entity 'COVID' named entity 'antibodies' named entity 'antibody' named entity 'antibody' named entity 'thrombosis' named entity 'plaque reduction neutralization test' named entity 'vaccine' named entity 'virus' named entity 'antigen' named entity 'convalescent plasma therapy' named entity 'serum samples' named entity 'enzyme' named entity 'RNA' named entity 'COVID' named entity 'oropharyngeal' named entity 'sulfuric acid' named entity 'antibody response' named entity 'cytopathic effects' named entity 'SARS-CoV-2' named entity 'inpatient care' named entity 'FBS' named entity 'COVID-19 virus' named entity 'virus' named entity 'tissue culture infectious dose' named entity 'virus' named entity 'SARS-CoV-2' named entity 'Personal protective equipment' named entity 'Nasopharyngeal' named entity 'clinical outcomes' named entity 'antibody' named entity 'Serum samples' named entity 'PPE' named entity 'Taiwan' named entity 'March 2020' named entity 'heart failure' named entity 'SARS-CoV-2' named entity 'correlation' named entity 'COVID' named entity 'correlation' named entity 'antibody' named entity 'antibody' named entity 'pharynx' named entity 'single center' named entity '5.6' named entity 'antigen' named entity 'antibody' named entity 'cardiac event' named entity 'China' named entity 'Antibody-Dependent Enhancement' named entity 'COVID-19' named entity 'IgG' named entity 'COVID' named entity 'antibody response' named entity 'viral load' named entity 'antibody response' named entity 'nucleic acid' named entity 'IgG antibodies' named entity 'COVID' named entity 'antibodies' named entity 'titer' named entity 'COVID-19' named entity 'viral load' named entity 'titer' named entity 'SARS' named entity 'antibody' named entity 'COVID-19' named entity 'Biosafety Level-3'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software